Trelegy Ellipta Overdosage

No data from clinical studies are available regarding overdose of Fluticasone furoate + Umeclidinium + Vilanterol (Trelegy Ellipta).
Symptoms and signs: An overdose of Fluticasone furoate + Umeclidinium + Vilanterol (Trelegy Ellipta) may produce signs, symptoms or adverse effects associated with the individual components' pharmacological actions (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Treatment: There is no specific treatment for an overdose with Fluticasone furoate + Umeclidinium + Vilanterol (Trelegy Ellipta). If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.
Cardioselective beta-blockade should only be considered for profound vilanterol overdose effects that are clinically concerning and unresponsive to supportive measures. Cardioselective beta-blocking drugs should be used with caution in patients with a history of bronchospasm.
Further management should be as clinically indicated or as recommended by the national poisons centre, where available.